CMP Therapeutics appoints ceo

Receives loan to support clinical trial of lead product for common cold

London-based CMP Therapeutics (CMPT) has appointed Neill Moray Mackenzie as chief executive.

Mackenzie joins the developer of therapeutics for colds, flu and allergy with a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore). He was most recently SVP for business development and corporate strategy at Medigene and ceo of Roji (London). In addition, MacKenzie was formerly a departmental head in vaccine r&d at Wellcome and a Wellcome lecturer in immunology at the University of London.

CMPT has received €1.5m convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported funding from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Drug Delivery

Rice University scientists create hydrogel platform for precision, long-lasting drug delivery

The researchers have developed a peptide hydrogel system that slows and extends drug release, improving treatment adherence and efficacy across therapies ranging from tuberculosis medication to insulin
Subscribe now